Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adenoid Cystic Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Adenoid Cystic Carcinoma. Displaying page 1 of 1.
    EudraCT Number: 2022-004188-25 Sponsor Protocol Number: ASST_FARM_ONCO_P-ACC_2022 Start Date*: 2023-03-03
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: P-ACC Trial - Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Medical condition: patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073370 Adenoid cystic carcinoma of salivary gland PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085951 Adenoid cystic carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022425-15 Sponsor Protocol Number: MK07 Start Date*: 2011-02-28
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)
    Medical condition: Adenoid-cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001220 Adenoid cystic carcinoma of the oral cavity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000066-22 Sponsor Protocol Number: BAY 43-9006 Start Date*: 2008-04-30
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma
    Medical condition: advanced salivary adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053231 Adenoid cystic carcinoma PT
    9.1 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000309-64 Sponsor Protocol Number: AL-ACC-01 Start Date*: 2019-10-24
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
    Medical condition: Adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001694-23 Sponsor Protocol Number: OOI/KEMB/2006-1 Start Date*: 2006-08-21
    Sponsor Name:National Institute of Oncology
    Full Title: Efficacy of cetuximab in locally advanced or metastatic adenoid cystic carcinoma. Phase II.
    Medical condition: Investigating the efficacy of cetuximab (Erbitux) in locally advanced or metastatic adenoid cystic carcinoma expressing EGFR.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002093-40 Sponsor Protocol Number: 104902 Start Date*: 2017-08-30
    Sponsor Name:Radboudumc
    Full Title: 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma
    Medical condition: Patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma or salivary duct carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003857-27 Sponsor Protocol Number: LUPSA Start Date*: 2020-01-23
    Sponsor Name:Radboudumc
    Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study.
    Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000693-35 Sponsor Protocol Number: ACC-LEN14 Start Date*: 2015-04-24
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract
    Medical condition: metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026121 Malignant neoplasm of major salivary glands recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001794-32 Sponsor Protocol Number: UC-0130/1619 Start Date*: 2016-11-23
    Sponsor Name:UNICANCER
    Full Title: A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck.
    Medical condition: recurrent and/or metastatic salivary glands carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066882 Metastatic salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000461-23 Sponsor Protocol Number: CA209-627 Start Date*: 2017-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
    Medical condition: Advanced/Metastatic malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA